Randomized, open-label phase II study of brigatinib and carboplatin plus pemetrexed and brigatinib alone for chemotherapy-naive patients with ALK-rearranged non-squamous non-small cell lung cancer: treatment rationale and protocol design of the B-DASH study (WJOG 14720 L)

BACKGROUND: The ALTA-1L study compared brigatinib with crizotinib in untreated ALK-rearranged non-small cell lung cancer (NSCLC) patients, demonstrating the efficacy of brigatinib. Although the median progression-free survival (PFS) of brigatinib group was 24.0 months, the one-year PFS rate was 70%....

Descripción completa

Detalles Bibliográficos
Autores principales: Wakuda, Kazushige, Kenmotsu, Hirotsugu, Sato, Yuki, Nakamura, Atsushi, Akamatsu, Hiroaki, Tachihara, Motoko, Miura, Satoru, Yokoyama, Toshihide, Mori, Keita, Nakagawa, Kazuhiko, Yamamoto, Nobuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10519075/
https://www.ncbi.nlm.nih.gov/pubmed/37749521
http://dx.doi.org/10.1186/s12885-023-11417-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10519075/
https://www.ncbi.nlm.nih.gov/pubmed/37749521
http://dx.doi.org/10.1186/s12885-023-11417-w

Ejemplares similares